⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for locally advanced urethral urothelial carcinoma

Every month we try and update this database with for locally advanced urethral urothelial carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and ImmunotherapyNCT04963153
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Recurrent Uroth...
Stage IIIB Blad...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Biospecimen Col...
Computed Tomogr...
Enfortumab Vedo...
Erdafitinib
18 Years - National Cancer Institute (NCI)
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 ExpressionNCT04953104
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Recurrent Uroth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIB Blad...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Unresectable Ur...
Diagnostic Labo...
Nivolumab
Relatlimab
18 Years - M.D. Anderson Cancer Center
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 ExpressionNCT04953104
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Recurrent Uroth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIB Blad...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Unresectable Ur...
Diagnostic Labo...
Nivolumab
Relatlimab
18 Years - M.D. Anderson Cancer Center
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaNCT04940299
Clinical Stage ...
Clinical Stage ...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Malignant Solid...
Metastatic Blad...
Metastatic Blad...
Metastatic Lung...
Metastatic Mela...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Uret...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Stage III Bladd...
Stage III Lung ...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIA Lung...
Stage IIIB Blad...
Stage IIIB Lung...
Stage IIIC Lung...
Stage IV Bladde...
Stage IV Lung C...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Lung ...
Stage IVB Lung ...
Unresectable Me...
Ipilimumab
Nivolumab
Tocilizumab
18 Years - M.D. Anderson Cancer Center
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 ExpressionNCT04953104
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Recurrent Uroth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIB Blad...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Unresectable Ur...
Diagnostic Labo...
Nivolumab
Relatlimab
18 Years - M.D. Anderson Cancer Center
Trying to Find the Correct Length of Treatment With Immune Checkpoint TherapyNCT04637594
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Pembrolizumab
Nivolumab
Atezolizumab
Durvalumab
Avelumab
18 Years - Alliance for Clinical Trials in Oncology
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial CarcinomaNCT04848519
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Pembrolizumab
Propranolol Hyd...
Nivolumab
Avelumab
18 Years - Emory University
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 ExpressionNCT04953104
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Recurrent Uroth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIB Blad...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Unresectable Ur...
Diagnostic Labo...
Nivolumab
Relatlimab
18 Years - M.D. Anderson Cancer Center
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial CancerNCT03237780
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Atezolizumab
Biopsy
Biospecimen Col...
Computed Tomogr...
Eribulin Mesyla...
18 Years - National Cancer Institute (NCI)
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial CancerNCT03237780
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Atezolizumab
Biopsy
Biospecimen Col...
Computed Tomogr...
Eribulin Mesyla...
18 Years - National Cancer Institute (NCI)
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: